BOULDER, Colo., May 02: KROMATID today announced it will present a transformative advancement in genomic integrity assessment at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting during the Analytics and Assay Development – Biosafety session.
Abstract #: ASGCT1713 Title: Establishing chromosome-scale benchmarks for detecting genomic instability in gene-edited cell therapies using high-depth cytogenetic analysis Presentation Time: May 15 at 9:00 AM (10-minute talk + 5-minute Q&A)
This presentation marks a critical step toward what KROMATID is building as the world’s first genomic intelligence platform – a new category that moves beyond fragmented assays to deliver integrated, decision-ready insight.
KROMATID’s latest work introduces a proprietary and first-of-its-kind approach to establishing chromosome-scale benchmarks for genomic instability – unlocking a fundamental gap in how cell therapies are evaluated.
For the first time, developers can contextualize the variants they observe – understanding what is normal versus abnormal – based on real, data-driven benchmarks. This shift transforms genomic integrity from a static measurement into a dynamic, interpretable framework for decision-making.
By leveraging high-depth cytogenetic analysis and a growing, structured dataset, KROMATID enables:
- Benchmarking of cell therapies against chromosome-level standards
- Contextual interpretation of structural variation
- Greater confidence in safety, quality, and development decisions
- A new level of clarity across the therapeutic lifecycle
“This is a defining moment for cell and gene therapy,” said Terry Opgenorth, CEO of KROMATID. “What KROMATID is building – a genomic intelligence platform – which brings clarity, context, and confidence to a space that has long operated without it. This realizes KROMATID’s vision to de-risk cell and gene therapy development and enable more therapies to get to market.”
As therapies become more complex, KROMATID’s approach signals a shift from isolated data points to integrated genomic intelligence – enabling developers to work in a way they never have before, starting at discovery and through IND-enabling studies to clinical development and commercialization.
KROMATID will be available throughout ASGCT at Booth #1654 to discuss how this breakthrough—and the broader genomic intelligence platform it enables is shaping the future of cell and gene therapy and will work to enable your success.
